Microsoft and OpenAI have changed their deal again

A federal judge seated a nine-person jury in Elon Musk’s lawsuit against OpenAI and Sam Altman, with the liability phase expected to conclude in about four weeks and damages claimed at $150 billion. Separately, Google employees petitioned management to reject Pentagon AI use cases, while Microsoft and OpenAI revised their partnership to let OpenAI sell across all cloud platforms, keep Microsoft as primary cloud partner through 2032, and preserve Microsoft’s 20% revenue share until 2030. The article also flags broader AI-sector developments including rising model deployment scrutiny, IPO ambitions, and competitive pressures among OpenAI, Anthropic, Microsoft, and Google.

Analysis

The real signal is not the lawsuit headline but the increasing separation between AI model ownership, cloud distribution, and capital intensity. Microsoft’s revised economics reduce headline dependency on OpenAI exclusivity while preserving monetization, which should support the multiple on Azure because it converts an adversarial relationship into a long-duration annuity with downside protection. The bigger beneficiary is likely the broader AI infrastructure stack: if OpenAI can route workloads across clouds, marginal compute procurement becomes more price-sensitive, putting incremental pressure on cloud yields and improving bargaining power for GPU/colocation providers outside Azure.

Google is in the trickiest position. Employee resistance around defense use is less about one contract and more about the internal friction between ethics, commercialization, and the need to offset enormous AI capex with enterprise/public-sector revenue. If the company yields, it risks activist labor backlash and reputational drag; if it resists, it cedes a category where rivals can position themselves as more “deployment-ready.” That dynamic is mildly negative for GOOGL near term, but could become positive if management uses the controversy to tighten product governance and win regulated customers who care more about auditability than raw model performance.

The Musk-Altman trial is a volatility event, but the first-order market impact is likely less about damages and more about discovery risk. Any testimony that highlights governance weaknesses, cap table ambiguity, or commercialization inconsistencies at OpenAI can reverberate across private AI valuations and IPO comps for months, especially if public investors begin discounting “foundational AI” businesses for litigation and regulatory overhang. Separately, the labor/defense angle is a quiet tailwind for Palantir: the more that hyperscalers hesitate on sensitive government workloads, the more the market may continue to assign a governance premium to vendors with established public-sector rails.

Key Decisions for Investors

• Long MSFT vs. short GOOGL for 4-8 weeks: Microsoft monetizes AI with lower governance friction and now has more pricing certainty; Google faces a higher probability of public controversy becoming a procurement overhang. Target 1.5-2.0x downside capture on the short leg if defense objections escalate.
• Buy MSFT on weakness, focused on 3-6 month horizon: the revised OpenAI terms de-risk the distribution story and make Azure cash-flow visibility better. Favor call spreads over outright equity to limit multiple compression risk if AI capex sentiment turns.
• Short a basket of private AI proxy names / late-stage AI venture comps into the next 1-2 months: the Musk-Altman trial can surface governance details that force repricing of “unicorn at any cost” assumptions. Use the litigation calendar as the catalyst, not fundamentals.
• Long PLTR vs. short GOOGL or broader hyperscaler basket for 1-3 months: if public-sector AI deployment slows for hyperscalers on ethics and classified-use concerns, Palantir’s sanctioned-workflow positioning should attract relative demand. Best expressed as a pair to isolate governance premium.
• Avoid chasing META on any AI-news bounce for now: the reported China unwind underscores that AI expansion is increasingly constrained by geopolitics and regulator sensitivity, which makes the stock more vulnerable to narrative reversals than its spend level would imply.